{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-078596","form_type":"8-K","ticker":"ELUT","cik":"0001708527","company_name":"ELUTIA INC.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.734124+00:00","generated_at":"2026-05-17T13:17:42.164748+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Elutia Q2 BioEnvelope revenue $3.5M (+33% YoY), EluPro sales surge 49% sequentially","bullets":["EluPro drug-eluting envelope revenue up 49% sequentially; now ~2/3 of BioEnvelope sales; average per-customer spend 130% higher vs legacy CanGaroo.","Total Q2 net sales $6.3M (flat YoY); SimpliDerm $2.0M (down from $2.6M); Cardiovascular $0.7M (down from $1.1M).","GAAP gross margin improved to 48.8% (vs 44.5%); adjusted gross margin 62.4% (vs 58.0%); net loss narrowed to $9.6M (vs $28.2M).","Litigation substantially resolved: settled 27 additional FiberCel cases for total 97 of 110; expect reduced litigation expenses.","Pipeline: progressing NXT-41 antibiotic biomatrix for breast reconstruction; FDA clearance targeted 2H26 (base) and 1H27 (drug-eluting); addresses $1.5B market."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-078596","json":"https://secwatch.observer/filing/0001104659-25-078596.json","markdown":"https://secwatch.observer/filing/0001104659-25-078596.md","text":"https://secwatch.observer/filing/0001104659-25-078596.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708527/000110465925078596/0001104659-25-078596-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708527/000110465925078596/tm2523438d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:17:42.164748+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}